Treatment for Klebsiella Pneumonia

Initial Assessment and Treatment Approach

For Klebsiella pneumonia infections, treatment should include ceftazidime-avibactam as first-line therapy for susceptible strains, or combination therapy with two or more in vitro active antibiotics for multidrug-resistant strains, as recommended by the Infectious Diseases Society of America 1, 2
Determine antimicrobial susceptibility testing results before initiating definitive therapy whenever possible, according to the Clinical Microbiology and Infection guidelines 2
For hospital-acquired or ventilator-associated pneumonia, broader spectrum agents are required due to higher likelihood of resistant strains, as stated by the World Journal of Emergency Surgery 3

Carbapenems are traditionally the treatment of choice for ESBL-producing strains, as recommended by the World Journal of Emergency Surgery 3
Consider carbapenem-sparing regimens when possible to reduce selection pressure for carbapenem resistance, according to the World Journal of Emergency Surgery 3
β-lactam/β-lactamase inhibitor combinations may be effective against some ESBL strains, as stated by the World Journal of Emergency Surgery 3
For severe infections caused by CRE susceptible only to polymyxins, aminoglycosides, tigecycline, or fosfomycin, treatment with more than one drug active in vitro is recommended, as advised by the Clinical Microbiology and Infection guidelines 2
Ceftazidime-avibactam is preferred as first-line therapy for infections caused by KPC-producing K. pneumoniae, according to the Clinical Microbiology and Infection guidelines 1, 2
For MBL-producing CRE (NDM, VIM), ceftazidime-avibactam in combination with aztreonam has shown significant reduction in 30-day mortality, as reported by the Clinical Microbiology and Infection 1
High-dose extended-infusion meropenem may be used as part of combination therapy if the meropenem MIC is ≤8 mg/L, as recommended by the Clinical Microbiology and Infection guidelines 2

For critically ill patients with severe infections or septic shock, combination therapy with two or more in vitro active antibiotics is associated with lower mortality, according to the Clinical Microbiology and Infection guidelines 2

For uncomplicated pneumonia: 7-10 days, as recommended by the Clinical Microbiology and Infection guidelines 1
For bacteremia or complicated infections: 10-14 days, as advised by the Infectious Diseases Society of America, with a strength of evidence rated as moderate 4

For patients with renal impairment, dose adjustment is necessary for many antibiotics, particularly aminoglycosides and polymyxins, as recommended by the Praxis Medical Insights: Practical Summaries of Clinical Guidelines, with a strength of evidence rated as high 5
Therapeutic drug monitoring is strongly recommended when using aminoglycosides or polymyxins to optimize dosing and minimize toxicity, according to the Praxis Medical Insights: Practical Summaries of Clinical Guidelines, with a strength of evidence rated as strong 4
Regular monitoring of renal function is essential when using polymyxins due to nephrotoxicity risk, as advised by the Praxis Medical Insights: Practical Summaries of Clinical Guidelines, with a strength of evidence rated as moderate 4

Delaying appropriate therapy is associated with increased mortality in severe Klebsiella infections, as reported by the Clinical Microbiology and Infection guidelines 2
Inadequate dosing of polymyxins can lead to treatment failure and resistance development, according to the Praxis Medical Insights: Practical Summaries of Clinical Guidelines, with a strength of evidence rated as high 4
Failure to adjust for renal function can lead to toxicity with many antibiotics used for Klebsiella treatment, as recommended by the Praxis Medical Insights: Practical Summaries of Clinical Guidelines, with a strength of evidence rated as moderate 5

Fluoroquinolones, such as levofloxacin 750mg daily or moxifloxacin 400mg daily, can be used as alternative monotherapy for community-acquired Klebsiella pneumoniae pneumonia, with high-dose levofloxacin specifically recommended for Klebsiella infections 6

Ceftazidime-avibactam demonstrates superior outcomes compared to colistin-based regimens in retrospective studies for KPC-producing K. pneumoniae respiratory infections 7
Combination therapy with two or more in vitro active antibiotics is strongly recommended for critically ill patients with severe CRKP pneumonia or septic shock, with lower 14-day mortality (OR 0.52, 95% CI 0.35-0.77) 7
Among critically ill patients with septic shock, combination regimens reduced 30-day mortality (HR 0.21, 95% CI 0.05-0.72) compared to monotherapy 8
The benefit of combination therapy is most pronounced in patients with INCREMENT scores of 8-15 (high risk for death), where adjusted HR was 0.56 (95% CI 0.34-0.91) 7

Polymyxin-based combinations should always include a companion drug, with common effective combinations including polymyxin plus carbapenem, polymyxin plus tigecycline, or polymyxin plus aminoglycoside 7
High-dose extended-infusion meropenem (2g IV over 3 hours every 8 hours) can be used in combination when meropenem MIC is ≤8 mg/L, even for carbapenem-resistant strains 7
Aminoglycoside-based regimens, such as gentamicin-containing regimens, showed significantly higher 30-day survival (adjusted HR 0.30, 95% CI 0.11-0.84) in colistin-resistant K. pneumoniae sepsis with respiratory source 8

Tigecycline should not be used as monotherapy for bacteremic pneumonia due to inferior outcomes compared to other agents, but high-dose tigecycline (200mg loading dose, then 100mg IV every 12 hours) in combination with other active agents may be considered 8